These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
NatComm_ADLumin-1.pdf (11.86 MB)

Smart Chemiluminescence Probes and Dual-Amplification of Signal for Detection of Amyloid Beta Species in Alzheimer’s Disease Model

submitted on 17.04.2020, 02:09 and posted on 20.04.2020, 11:25 by Jing Yang, Wei Yin, Richard Van, Keyi Yin, Peng Wang, Chao Zheng, Biyue Zhu, Kathleen Ran, Can Zhang, Yihan Shao, Chongzhao Ran
Fluorescence and chemiluminescence imaging are the most widely applied optical emissive imaging
methods in biomedical research. “Smart” (turn-on) fluorescence imaging has been routinely used for in
vitro, cellular, and in vivo imaging; however, smart chemiluminescence imaging has been rarely explored.
In this report, we designed chemiluminescence probe ADLumin-1 and validated that ADLumin-1 was a
smart chemiluminescence probe for amyloid beta (Ab) species, evidenced by a 216-fold amplification of
chemiluminescence intensity upon mixing with Abs in vitro. In vivo two photon imaging indicated that
ADLumin-1 could efficiently cross blood-brain- barrier (BBB) and provided excellent contrast both for Ab
plaques and cerebral amyloid angiopathy (CAA). In vivo whole brain imaging showed that the
chemiluminescence signal of ADLumin-1 from 5-month-old transgenic AD (5xFAD) mice was 1.80-fold
higher than that from the age-matched wild-type mice. Moreover, we demonstrated that it was feasible to
further dually-amplify signal via chemiluminescence resonance energy transfer (DAS-CRET) using two
non-conjugated smart probes (ADLumin-1 and CRANAD-3) in solutions, brain homogenates, and in vivo
whole brain imaging. Our results showed that DAS-CRET could provide a 2.25-fold margin between 5-
month-old 5xFAD mice and wild type mice. To our knowledge, this is the first report that a
chemiluminescence probe could be used for detecting Ab species both in vitro and in vivo. Although
ADLumin-1 was designed for Abs, we believe that our strategy could be potentially extended to a wide
range of targets, including other aggregating-prone proteins. Notably, our results suggested that the
strategies for turning-on fluorescence could be used for amplifying chemiluminescence, and we believe that
our studies could inspire considerably more research on chemiluminescence imaging


NIH R01AG055413

NIH R21AG059134


Email Address of Submitting Author


Massachusetts General Hospital and Harvard Medical School



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest